INAPSINE Drug Patent Profile
✉ Email this page to a colleague
When do Inapsine patents expire, and when can generic versions of Inapsine launch?
Inapsine is a drug marketed by Rising and is included in one NDA.
The generic ingredient in INAPSINE is droperidol. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the droperidol profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Inapsine
A generic version of INAPSINE was approved as droperidol by AM REGENT on October 24th, 1988.
Summary for INAPSINE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 103 |
Clinical Trials: | 1 |
Patent Applications: | 4,076 |
Formulation / Manufacturing: | see details |
DailyMed Link: | INAPSINE at DailyMed |
Recent Clinical Trials for INAPSINE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Lake Erie College of Osteopathic Medicine | Phase 3 |
Mercy Health Ohio | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for INAPSINE
US Patents and Regulatory Information for INAPSINE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Rising | INAPSINE | droperidol | INJECTABLE;INJECTION | 016796-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |